|
|
Speakers 
 Steve Burton,
Chief Operating Executive,
Prometic Biosciences, United Kingdom
Dr Burton is the Chief Executive Officer of Prometic Biosciences Ltd (PBL), a wholly owned subsidiary of ProMetic Life Sciences Inc. PBL is focused on the development of materials and technology used in a variety of bio-pharmaceutical applications, most notably the manufacture of therapeutic proteins (from native and recombinant sources) and bio-contaminant removal.
Dr Burton gained his Ph.D. at the University of Cambridge, U.K. researching novel affinity ligands for use in protein purification and as artificial coenzymes. He joined Delta Biotechnology Ltd (now NovozymesDelta) in 1986 as a research scientist and moved to Affinity Chromatography Ltd in 1988 as Research Manager prior to his appointment as R&D Director in 1993 following the establishment of a successful R&D group which won the Queens Award for Technological Achievement in 1996. Affinity Chromatography Ltd became a wholly owned subsidiary of Prometic Life Sciences in 1999 subsequent to which Dr Burton held the positions of Vice President, Research and Development and Executive Vice President/Chief Scientific Officer until his appointment as CEO in February 2006.
|
 Dr John Curling,
President,
John Curling Consulting, Sweden
John Curling works as an independent consultant and is currently Senior Scientist and Consultant with ProMetic BioSciences Ltd. He is also a member of the Scientific Advisory Committee of the company and is a consultant to the Core Management Team of the ProMetic – American Red Cross joint Plasma Protein Purification Project.
After graduating in chemistry from the University of Sussex, UK, John Curling entered the laboratory and industrial purification arena in 1967 and started to build a process chromatography business at Pharmacia in 1972. Research on blood plasma proteins was carried out primarily during the period 1972-1982. He held various management positions and was President of Pharmacia’s Process Separation Division from 1984 until 1990. In the early 1980’s John Curling was also Marketing Director in a Joint Venture partnership with the engineering and fermentation company Alpha Laval AB/Chemap AG. In 1986 he was involved in a major acquisition (LKB Produkter) and the subsequent integration and rationalisation of the merged companies.
He is the author of numerous publications and was a contributor and editor of “Methods of Plasma Protein Fractionation”. He is on the Editorial Advisory Board of “BioPharm International”.
John Curling was Chairman of the Board of the ‘‘Recovery Conference Series’’ from 2001 to 2003, and was a Co-chair of the “Recovery of Biological Products 10” Conference held in Mexico in 2001. He has also worked as a Temporary Advisor and Consultant to the World Health Organisation South East Asia Region on technologies for blood plasma fractionation.
|
 Patrick Deruytter,
Director, Engineering Services, Asia Pacific,
Emerson Process Management, Singapore
Mr Deruytter is Director of Emerson’s Engineering & Services in Singapore where he has overall responsibility for all operations, project executions and services for the Systems and Solutions division in Asia Pacific. His expertise includes the management of large project portfolio in the oil and gas, petro-chemical, chemical, mining and pharmaceutical industries. He has also developed and introduced new services such as SIS (safety instrumented services), APC (advanced process control), PIMS and MES in the AP region.
Mr Deruytter has a Master of Process Automation as well as a Bachelor of Industrial Engineer Electronics from the Industriele Hogeschool v/h Rijk Gent (Belgium). He then completed his management program at the Minnesota Management Institute, University of Minnesota. He began his career as an Instrumentation Engineer for ABAY, then progressed to Systems Engineer for Fisher Controls in Belgium. He was then Project Engineer for Fisher-Rosemount Belgium in 1993, during which, he advanced from Technical Service Manager to Service Manager. From 1997 onwards, he was relocated as Marketing Director for RS3 in Fisher-Rosemount in USA where he assumed full responsibility for the worldwide marketing & North America sales for RS3. After year 2000, he went on as Marketing Director Systems for Emerson Process Management EMA (previously Fisher-Rosemount); advanced to Project Director for Emerson Process Management and in 2003 came to where he is now, Director of Engineering & Services Asia Pacific. During the period of his studies and career, he has also accomplished numerous scholarship programs.
Mr Deruytter can converse up to 4 languages and has more than 20 years of industry experience behind him.
|
 William Downey,
President,
HighTech Business Decisions, USA
Mr. Downey is president and managing director of HighTech Business Decisions, a consulting company that specializes in market research for business-to-business biotechnology, pharmaceutical manufacturing, medical and electronic products. HighTech Business Decisions has been serving the biopharmaceutical contract manufacturing industry for over ten years. Mr. Downey has over 25 years of industry experience, and he has held various positions in marketing, sales, strategy and finance for both private and public companies. Mr. Downey has a Masters in Business Administration from Washington University in St. Louis and Bachelors from the University of Michigan in Ann Arbor.
|
 Sarah E Frew,
Research Associate, Program on Life Sciences, Ethics and Policy, McLaughlin Rotman Centre for Global Health, UHN|UCMM,
University of Toronto, Canada
Sarah E. Frew is a Research Associate at the McLaughlin-Rotman Centre for Global Health, Program on Life Sciences, Ethics and Policy, at the University of Toronto in Canada. Her research focuses on how homegrown health biotechnology firms from emerging countries develop products targeted to address local health needs. Dr. Frew has conducted on-site visits of over 60 innovative small to medium-sized health biotechnology companies in India, China, Brazil and South Africa. This work has led to a keen understanding of (1) how these nascent sectors have developed capabilities along the product development value chain and (2) the strategies utilized by the firms to survive and grow amid a myriad of challenges related to operating in a developing world context. These findings are relevant to biotechnology firms seeking partnerships, venture capitalists seeking investment opportunities, foundations interested in global health solutions, and developing world governments seeking ideas about successful innovation strategies, and will help to inform the debate around biotechnology in health and economic development. Dr. Frew completed her doctoral studies in Biology at the Massachusetts Institute of Technology, where her research addressed the cellular and molecular events that control cell behaviour during invasion and metastasis of malignant cancer cells.
|
 Uwe Gottschalk,
Vice President, Purification Technologies,
Sartorius Biotech, Germany
Dr. Uwe Gottschalk has been the Vice President of Purification Technologies at Sartorius since April 2004.
Earlier, he worked at Bayer Health Care, and just before joining Sartorius, he headed the GMP Protein Purification unit in Wuppertal, Germany. Moreover, the 45-year-old is dedicated to fostering research and science: He additionally works as a lecturer for the first accredited Master’s Degree in Pharmaceutical Medicine in Essen, Germany, and also holds lectures at the polytechnical college Ecole Polytechnique Fédérale de Lausanne (EPFL) in Lausanne, Switzerland. For six years, he has also been active as a volunteer at the Friedrich-Ebert Foundation on the university committee for awarding scholarships to students.
|
 Frank Jackson,
VP, Manufacturing,
Genentech, USA
Frank Jackson is Vice President and General Manager of Genentech's Vacaville Product Operation with responsibilities for Manufacturing, Facilities Services, Production Services and Technology.
Prior to joining Genentech in 1981, Frank spent several years in biochemical research, followed by five years as Technical Manager for Cyanamid of Great Britain, a wholly owned subsidiary of American Cyanamid. In 1990 he was promoted to Senior Director of Biochemical Manufacturing and in 1994 to the newly created position of General Manager at Vacaville. In 2002 he became Vive President and an officer of the company He has a B.S. in Biochemistry from St Andrews University, a M.S. in Microbiology and a Diploma in Management Studies.
|
 Ni Jian,
CEO and Chief Scientist,
Human Antibodomics, China
Dr. Jian Ni is CEO and Chief Scientist of Human Antibodomics Inc., Chairman of Human-Human Hybridomas LLC. He is Chairman, Committee of Medicinal Biotech,Vice President, Shanghai Society of Biotechnology, Chairman, Committee of Interferon and Other Cytokines, Executive Director, Chinese Society of Microbiology, Director, Committee of Monoclonal Antibody, China Medicinal Biotech Association, Co-Chairman, Committee of Key Laboratory of Antibody Technique, Ministry of Health, President, Chinese Biopharmaceutical Association, USA, 2001-2003, Director, Chinese Biopharmaceutical Association, USA, 1999-2007. He received many honors and awards, such as Award for national outstanding returned scholars, 2003, Shanghai excellent returned scholars, Scientific foresight advisor for Shanghai government, Privileged expert of China Department of State (2005), Award for outstanding achievement in development of Pudong New Area (2005). He served as an advisor to several government and professional organizations, has been frequently invited to be Meeting Chair, Session Chair or Committee Member for several major international conferences for Biopharma and Antibody . He is currently a Visiting Professor of Shanghai Jiao Tong University, Second Military Medical University and Nanjing Medical University. Dr. Ni co-founded Human Antibodomics Inc., Shanghai Fuchun Zhongnan Biotech Inc., CYBRDI, Inc., USA and ShanXi Chao Ying Biomedicine R&D Ltd., China.
Dr. Jian Ni obtained his M.D. from Second Military Medical University and Ph.D. from University of Cambridge. Dr. Ni was a Post-doctoral Fellow at the National Cancer Institute and University of California, Irvine. He is an American Society of Clinical pathologists board certified Specialist in Immunology. Dr. Ni was a Senior Scientist of Human Genome Sciences, Inc., and has many years of experience in biomedical research, immunology, oncology and protein chemistry, and industrial experience in functional genomics, therapeutic protein and antibodies discovery and development. He has published more than 80 scientific articles in top scientific journals (IF >600), Inventor of 148 issued US patents, three of the HGS genomic derived clinical trial antibodies were based on his patents. A few apoptosis related genes discovered by Dr. Ni and his collaborators were reviewed by Science Journal as top ten breakthroughs of the year 1996.
|
 Eric Langer,
Managing Partner,
BioPlan Associates, USA
Eric Langer has over 19 years experience in biotechnology and life sciences international marketing management, market assessment, and publishing. He is an experienced biotechnology author, publisher, marketing practitioner, and strategist. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published, edited and authored numerous books, reports, and major studies on topics including: Advances in Biopharmaceutical Technology in China, Advances in Large-scale Biopharmaceutical Manufacturing, Biopharmaceuticals in the US Market, cell culture reports, media, sera, tissue engineering, stem cells, diagnostic products, blood products, genetics, DNA/PCR purification, blood components, and many others. He lectures extensively on pricing and channel management topics. He has developed numerous courses, classes and seminar programs, including Marketing in a Regulated Environment, Marketing Technical Products, and TechniManagement™-- In 1989 he co-founded BioPlan Associates, Inc. a biotechnology and life sciences marketing company that provides information, market research, pricing, and market analysis to biotechnology and healthcare organizations. He has launched and managed marketing programs for product lines ranging from $500k to $500 million. His company works with both large and small clients at commercial biotechs, non-profit organizations, and governments in assessing and evaluating markets, and marketing strategies and tactics. He teaches at Johns Hopkins University and American University: Biotechnology Marketing, Marketing Management, Services Marketing, Advertising Strategy, and Bioscience Communication.
|
 Ker Yin Lee,
Executive Deputy General Manager,
Shanghai United Cell Biotechnology, China
Dr. Lee was born in 1955 and received his primary and secondary education in Singapore. In 1981, Dr. Lee obtained his BSc (Hons) Degree in Microbiology from the University of Glasgow. During his study, he was awarded the John Hunter Medal in Biochemistry. In 1982, Dr. Lee also received scholarships from the University of Glasgow and the Commonwealth University Councils to pursue his PhD degree in Microbiology from the University of Glasgow. In 1984, Dr. Lee continued his post-doctor research at the Institute of Virology. Dr. Lee joined LKB Produkter Ltd in Sweden in 1985 and served as the General Manager of their Biotechnology Division in China. In 1988, Dr. Lee returned to Singapore to assist in the formation and business development of Diagnostic Biotechnology Co Ltd, the first biotechnology company in Singapore, and successfully opened up the European and Asian markets thru the establishment of Geneva, Bangkok and Jakarta offices. In 1993, Dr. Lee moved to China, working for several pharmaceutical companies involved in bio-therapeutics and vaccines. In 2002, Dr. Lee joined Shanghai United Cell Biotechnology Co., Ltd as Executive Deputy General Manager.
|
 Feng Li,
Senior Engineer, Process Development,
Genentech, USA
Feng Li is a Senior Engineer at Genentech Process Development, where his responsibilities included CHO cell culture process development, bioreactor scale up, process tech transfer, and cGMP manufacturing tech support. Before joining Genentech, he was a Senior Scientist at Amgen, Thousand Oaks. Prior to joining Amgen in 2004, Feng started his career as a Process Engineer at Tanox, Inc. in early 2002, where he focused on NS0 cell fed-batch media development and process optimization for therapeutic antibody production. Feng received his Ph.D. degree in Chemical Engineering from Rice University, Houston TX, in 2002. He also obtained a M.S. from Tsinghua University and a B.S. from Jiaotong University in China.
|
 Sun Li,
Managing Director,
Amoytop Biotech, China
Chief Executive Officer, Xiamen Amoytop Biotech Co., Ltd.
Chief Executive Officer, Biosteed Gene Expression Tech. Co., Ltd.
Deputy Committee Member, for Year 2006 of Biotech Products Quality Control Committee, China Medicinal Biotech Association
Standing Committee Member, for Year 2005 of Gene Engineering Polypeptide Drugs and Vaccine Committee, China Medicinal Biotech Association
|
 Richard van Duyse,
Chief Operating Officer,
Tianyuan Biopharmaceutical, China
Richard van Duyse, Dutch nationality, joined in 2005 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd, Hangzhou, China; a private vaccine manufacturing and sales company.
As COO, he is responsible for all operations and for ‘the internationalization processes’ in particularly aspects such as (GMP) quality, technology transfer, (project) management style, documentation, regulatory, etc. to ensure a sustainable development of Tianyuan.
Prior to joining Tianyuan, Richard van Duyse worked in RIVM and SVM (Director of Operations) in the Netherlands for over 25 years, respectively for Perfetti-vanMelle (General Manager) and Jacobs Engineering (Senior Consultant / Director Pharma Northern Europe), gaining broad professional, management and consultancy experience. Responsibilities during that time included production, project management and business development, through a number of assignments oversea and at country offices.
|
 Hao Wang,
Deputy Director,
Cancer Institute of the Second Military Medical University, China
Dr. Hao Wang is the deputy director of the Cancer Institute of the Second Military Medical University. He is also the deputy director of Shanghai Antibody Engineering Technology Center. He was born in 1968 and received his primary and secondary education in China. In 1991, Dr. Wang obtained his MD degree from Second Military Medical University (SMMU) in Shanghai. In 1997, he obtained his PhD degree from Eastern Institute of Hepatobilary Surgery of SMMU. In 1997, Dr. Wang continued his post-doctor research at the Sidney Kimmel Cancer Institute in San Diego, USA. After returning to China in 1999, Dr. Wang have served as assistant professor, associate professor, and professor in the Cancer Institute of SMMU. In the past 8 years, Dr. Wang focused on the R&D of antibody drugs, especially in the pre-clinical research of anti-tumor humanized antibody drugs. He played important role in the establishment of Shanghai Antibody Engineering Technology Center, and the marketing of the first recombinant antibody drug, entanercept, in China.
|
 Scott Wheelright,
President,
Strategic Manufacturing Worldwide, USA
Scott M. Wheelwright, Ph.D. is founder and president of Strategic Manufacturing Worldwide, Inc., a consultancy focused on bringing products to market. SMW provides technical expertise to biotech and related industries in the areas of manufacturing, process development, compliance, facilities, and business development, with particular emphasis on strategic planning and projects in Asia.
Dr. Wheelwright has over 20 years experience in solving the challenges companies encounter when bringing biotech and other medical products out of research and into the commercial marketplace. Dr. Wheelwright has led the development of products for cancer, wound healing, infectious diseases and cardiovascular therapy.
Previous employment includes positions at Scios, Chiron and Abbott. Dr. Wheelwright obtained his Ph.D. degree in chemical engineering from the University of California at Berkeley and performed post-doctoral studies at the Max Planck Institute in Germany. Dr. Wheelwright is the author of a book on protein purification and has published many papers on process design and manufacturing for biotechnology. Dr. Wheelwright can be reached by email at info@smwbiotech.com.
|
 Li Xiaoqiang,
General Manager,
Tasly Jenner Biotech, China
Dr Li has combined experiences in clinical medicine and pharmaceutical biologics. Graduated from medical school in early 80’s in China and finished residency training in the United States. He’s practiced medicine and was responsible for residency training and clinical management. He’s also trained in Molecular Biology and Business Management in US. After 10 years of clinical practice, he came to China to set up his company, engaging in developing vaccine and biologics. He has been responsible for developing one vaccine and three recombinant protein drugs. He was also the general manager of Tianjin Tasly Biotech Venture Capital management Company between 2003 and 2005, and had extensive experiences in valuating and investing in biotech projects.. He is currently the managing director for Tasly-Jenner Biotechnology Co., a company in manufacturing subunit influenza vaccine. He is also the director of Tasly Biopharm Research Institue and Executive VP for Shanghai Tasly Pharmaceutical Co., a company engaging in mammalian cell culture and recombinant protein manufacturing. His main interest is in large scale manufacturing of biologics.
|
 Lei Zhang,
Head of China Office,
Biologics Consulting Group, China
CURRENT POSITION
(Apr. 2007 - present) Head, China Office Biologics Consulting Group Inc.
Boyds, MD
Ph.D. Cellular Biology and Immunology, Dept. Of Cellular Biology, University of Georgia, Athens, Georgia (1997)
M.S. Immunology, Dept. Of Immunology of Malaria, First Army Medical College, Guangzhou, People's Republic of China (1987)
M.D. South China Medical College, People's Republic of China (1984)
|
 Dr Joe Zhou,
Scientific Director, Process Development,
Amgen, USA
Dr. Joe X Zhou is a Principal Scientist at Process Development Department, Amgen Inc. Dr. Zhou’s expertise is in non-cGMP and cGMP protein/antibody therapeutics purification/production. He has experience in all aspects of process research, process optimization, viral clearance, and characterization as well as laboratory set up and project management. Dr. Zhou accomplished six patent applications and five process publications after since Amgen in 2004. Dr. Zhou has received many awards and has been invited as a speaker for many international conferences. He has over 45 full research articles and 12 abstracts published in peer- reviewed journals. Dr. Zhou is also a co-author for six registered US patents before Amgen. Dr. Joe Zhou has his Ph.D. degree in Biopharmaceutical Sciences from Queen’s University of Belfast, M.S. in Enzymology/Biochemistry and B.S. in Microbiology from Liaoning University. He has been a member of American Association of Pharmaceutical Scientists for over 10 years and currently is a member of American Chemistry Society.
|
 Desheng Zhou,
General Manager,
Beijing Kawin Bio-Tech, China
|
 Jian Wei Zhu,
Associate Director, Biopharmaceutical Development Program,
SAIC Frederick, National Cancer Institute at Frederick, USA
After receiving degrees in biochemical engineering and microbial genetics, Dr. Jianwei Zhu spent his post-doctoral research at MIT and Harvard Medical School to develop his expertise for the career in biopharmaceutical development. Since 1997, Jianwei has been playing technical leadership role in the Biopharmaceutical Development Program at SAIC-Frederick, National Cancer Institute at Frederick for developing more than 20 bioprocesses mainly for phase I and II clinical trials including recombinant human cytokines, immunotoxins, plasmid DNA and viral vaccines, therapeutic enzyme, and both fermentation and cell culture processes for biologics production.
His expertise in clinical development has been recognized internationally. He was invited by International Vaccine Institute (United Nation found) to Vietnam for GMP training to Vietnamese FDA and auditing on a vaccine production facility. During 2004-2006 he was invited by National Institute of Health (USA) to provide expert opining on selecting GMP facilities for two NIH supported vaccine development through several pre-auditing assessment and GMP auditing. In 2006 he has provided GMP training and facility auditing for a Taiwanese vaccine company Adimmune that is major supplier to Taiwan vaccine market. Besides, Dr. Zhu provided numerous scientific presentations, consultation services on clinical production, clinical production process development, GMP facility design and feasibility analysis, as well as quality management system and validation including to the organizations in China, Shanghai Institute of Pharmaceutical Industry and Chinese CDC.
|
|
|
|
